[redactions made under s47F of the FOI Act]
logo)?
10. List any issues (such as
Could you please clarify whether any
particular risks, treatment
specific searches will be undertaken
considerations or sociocultural
to identity any issues for Aboriginal
considerations) identified as
and Torres Strait Islander peoples or
relevant to Aboriginal and Torres
any other groups identified?
Strait Islander peoples or any
other groups (e.g. culturally and
linguistically diverse (CALD)
groups) which will be considered
as part of the guideline scope, and
describe how these issues have
been addressed in the evidence
review and formulation of
recommendations.
14. Describe the process which will NHMRC’s Procedures and
be used to reach expert or group
Requirements D.4 – D.6 discuss the
consensus in the development of
process for developing
recommendations.
recommendations. Can you expand
on this process? For example a
quorum of members, dissenting
opinions documented etc.
17. Describe the processes that
Could you please confirm some of
are in place to collaborate with
the advice that the represented
organisations that are
organisations on the GDG have
producing/have produced advice
produced / are producing?
in related areas. For example they
may be involved in the review of
evidence, review of drafts, and/ or
notified when potentially
conflicting recommendations are
proposed.
24. Provide details of any
Could you please provide a little
controversial or contentious issues more detail about these
associated with the guideline
organisations and the past
content or development process.
controversies of the guidelines? This
will help us prepare our internal
responses in the unlikely chance we
are questioned about it.
Many thanks & Kind regards,
Sally
Sally Wright
Senior Project Officer, Clinical Practice Guidelines
Research Translation
National Health and Medical Research Council
xxxxx.xxxxxx@xxxxx.xxx.xx
+61 03 8866 0411
Hours: Please note I do not work Wednesdays.
2
nhmrc.gov.au
I acknowledge the Traditional Custodians of the lands around Australia and pay my respects to
Elders past and present.
-----Original Message-----
From:
Sent: Monday, 28 June 2021 3:52 PM
To: Clinical Guidelines <xxxxxxxxxxxxxxxxxx@xxxxx.xxx.xx>
Cc: Mark Bellgrove <xxxx.xxxxxxxxx@xxxxxx.xxx>;
Subject: Re: ADHD guideline progress report [SEC=OFFICIAL]
Dear Sally,
Thank you for your response about the new Council and meeting dates. We will aim to submit
in time for the March 2022 (or thereabouts) meeting.
So sorry for forgetting the Appendices! They are attached here.
Best wishes,
Diagnosis, management and treatment of ADHD - an Australian ADHD Professionals
Association (AADPA) evidence-based guideline, in development.
Monash University Affiliate, Monash Centre for Health Research and Implementation
E:
I acknowledge the Traditional Owners and Custodians of the lands on which I live and work
and pay my respect to Elders both past and present.
On 28/06/2021 3:37 pm, Clinical Guidelines wrote:
> Dear
>
> Thank you for your progress email/report and welcome
. Nice to e-meet you!
>
> I too want to apologise for the delay in responding to you. We've had some staff changes
which has delayed our response to some of our work.
>
> July 2021 marks the new triennium for NHMRC, with the appointment of new members to
Council and Principal Committees for a three year period.
>
> Council meeting dates are not confirmed until the new Council has been appointed. NHMRC
is in the process of doing this now. I anticipate that the first meeting of the new Council will be
mid October 2021. The following dates are usually March and June. Once we have more
information we can pass that on.
>
> Upon reading your report I note that it refers to appendices A, B & C. Could you please send
this through for review.
>
> Many thanks & Kind regards,
> Sally
>
3
>
> Sally Wright
> Senior Project Officer, Clinical Practice Guidelines Research
> Translation National Health and Medical Research Council
> xxxxx.xxxxxx@xxxxx.xxx.xx
> +61 03 8866 0411
> Hours: Please note I do not work Wednesdays.
>
> nhmrc.gov.au
>
>
>
> I acknowledge the Traditional Custodians of the lands around Australia and pay my respects
to Elders past and present.
>
>
>
> -----Original Message-----
> From:
> Sent: Tuesday, 15 June 2021 3:41 PM
> To: Clinical Guidelines <xxxxxxxxxxxxxxxxxx@xxxxx.xxx.xx>
> Cc: Mark Bellgrove <xxxx.xxxxxxxxx@xxxxxx.xxx>;
> Subject: ADHD guideline progress report
>
> Dear Sally and Stephanie,
>
> Apologies for the long silence. We have been getting through as much evidence review as
possible. I have cc'd
into this email.
>
is managing our deliverables and liaising with the clinical groups to ensure they are
supported to interpret the evidence and draft recommendations. I am happy to remain the
NHMRC contact.
>
> Our next GDG meeting in July is intended to discuss recommendations and GRADE evidence
to recommendation considerations. We hope to begin public consultation in October.
>
> Please find attached the progress report according to the NHMRC template. I note that we
will miss the October NHMRC guideline council meeting. Is there a date for the next council
meeting after October?
>
> Thank you and best wishes,
>
>
>
4
